Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADC-AVP04
- Development stage
- Unknown
- Lead developer
- Avipep
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ADC-AVP04 is an investigational antibody-drug conjugate (ADC) developed by Avipep for the treatment of multiple adenocarcinomas, including ovarian, gastric, and prostate cancers. The drug utilizes Avipep's proprietary Avibody™ platform, which consists of a compact, bivalent diabody format derived from the murine monoclonal antibody CC49. ADC-AVP04 specifically targets tumor-associated glycoprotein 72 (TAG-72), a cell-surface glycoprotein highly expressed on various epithelial cancers but minimally expressed in normal tissues. The Avibody is conjugated to the microtubule-disrupting payload monomethyl auristatin E (MMAE) via a trans-cyclooctene (TCO) linker or a protease-cleavable valine-citrulline (vc) linker. In a pre-targeting approach developed in collaboration with TagWorks, ADC-AVP04 is administered first to localize to the tumor, followed by a systemic tetrazine activator that triggers the precise release of MMAE within the tumor microenvironment. This design aims to maximize therapeutic efficacy while minimizing systemic toxicity and avoiding renal clearance.
- Other names
- ADC AVP 04ADC AVP-04Avibody ADC-AVP04
02
Targets
STn-MUC1 (Sialyl-Tn-MUC1)TAG-72
Beyond the preview
Go deeper on ADC-AVP04.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADC-AVP04.